Peer-reviewed veterinary case report
Using saliva tests to track treatment in dogs with mouth melanoma
By Ploypetch, Sekkarin et al.·Published in PloS one·2021·Department of Physiology·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Salivary proteomics in monitoring the therapeutic response of canine oral melanoma.
- Species:
- dog
Plain-English summary
A group of dogs with oral melanoma (a type of mouth cancer) were treated with surgery and the chemotherapy drug carboplatin to see how their saliva could help monitor their response to treatment. Researchers found that a specific protein in saliva, called ubiquitin D (UBD), could indicate how well the dogs were doing. Dogs that had a higher ratio of free UBD to conjugated UBD before surgery tended to have shorter survival times after treatment. This suggests that measuring UBD levels in saliva could help predict how long dogs with oral melanoma might live after treatment.
People also search for: dog oral melanoma treatment · canine cancer saliva test · carboplatin for dog cancer
Abstract
Saliva biomarkers are suitable for monitoring the therapeutic response of canine oral melanoma (COM), because saliva directly contacts the tumor, and saliva collection is non-invasive, convenient and cost effective. The present study aimed to investigate novel biomarkers from the salivary proteome of COM treated with surgery and a chemotherapy drug, carboplatin, 1-6 times, using a liquid chromatography-tandem mass spectrometry approach. The expression of a potential salivary biomarker, ubiquitin D (UBD), was observed and verified by western blot analysis. A significantly increased ratio of free UBD (fUBD) to conjugated UBD (cUBD) was shown in the pre-surgery stage (PreS) in OM dogs with short-term survival (STS) (less than 12 months after surgery) compared with that with long-term survival (more than 12 months after surgery). In dogs with STS, the ratio was also shown to be augmented in PreS compared with that after surgery, followed by treatment with carboplatin twice, 4 and 5 times [After treatment (AT)2, AT4 and AT5]. In addition, the expression of fUBD was enhanced in PreS compared with that of AT2 in the STS group. In conclusion, this study revealed that a ratio of fUBD to cUBD in PreS was plausibly shown to be a potential prognostic biomarker for survival in dogs with OM.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34411146/